N/A N=36 Randomized Single-blind Treatment

Cannabidiol Effects on Blood Alcohol Level and Intoxication

Alcohol Use Disorder

Bottom Line

View on ClinicalTrials.gov: NCT06105138 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Sep 2024

Primary outcome: Primary: Breath Alcohol Concentration (BrAC) — 0.065; .067; .070 g/dL

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: 200mg Cannabidiol oral solution (Dietary_supplement); 30mg Cannabidiol oral solution (Dietary_supplement); Placebo (Dietary_supplement)
Age: Adult · 21+ yrs
Sex: All
Sponsor: Colorado State University
Primary completion: Mar 2022

Outcome Measures

Outcome	Result	p-value
PRIMARY Breath Alcohol Concentration (BrAC)	.013; .012; .013	—
PRIMARY Breath Alcohol Concentration (BrAC)	.013; .012; .013	—
PRIMARY Breath Alcohol Concentration (BrAC)	.013; .012; .013	—
PRIMARY Breath Alcohol Concentration (BrAC)	.013; .012; .013	—
PRIMARY Breath Alcohol Concentration (BrAC)	.013; .012; .013	—
PRIMARY Breath Alcohol Concentration (BrAC)	.013; .012; .013	—
PRIMARY Breath Alcohol Concentration (BrAC)	.013; .012; .013	—
PRIMARY Breath Alcohol Concentration (BrAC)	.013; .012; .013	—
PRIMARY Breath Alcohol Concentration (BrAC)	.013; .012; .013	—
PRIMARY Biphasic Effects of Alcohol (BAES)--Stimulation Subscale	4.96; 4.89; 6.78	—
PRIMARY Biphasic Effects of Alcohol (BAES)--Stimulation Subscale	4.96; 4.89; 6.78	—
PRIMARY Biphasic Effects of Alcohol (BAES)--Stimulation Subscale	4.96; 4.89; 6.78	—
PRIMARY Biphasic Effects of Alcohol (BAES)--Stimulation Subscale	4.96; 4.89; 6.78	—
PRIMARY Biphasic Effects of Alcohol (BAES)--Stimulation Subscale	4.96; 4.89; 6.78	—
PRIMARY Biphasic Effects of Alcohol (BAES)--Stimulation Subscale	4.96; 4.89; 6.78	—
PRIMARY Biphasic Effects of Alcohol (BAES)--Stimulation Subscale	4.96; 4.89; 6.78	—
PRIMARY Biphasic Effects of Alcohol (BAES)--Stimulation Subscale	4.96; 4.89; 6.78	—
PRIMARY Biphasic Effects of Alcohol (BAES)--Stimulation Subscale	4.96; 4.89; 6.78	—
PRIMARY Biphasic Effects of Alcohol--Sedation Subscale	8.07; 6.70; 6.89	—
PRIMARY Biphasic Effects of Alcohol--Sedation Subscale	8.07; 6.70; 6.89	—
PRIMARY Biphasic Effects of Alcohol--Sedation Subscale	8.07; 6.70; 6.89	—
PRIMARY Biphasic Effects of Alcohol--Sedation Subscale	8.07; 6.70; 6.89	—
PRIMARY Biphasic Effects of Alcohol--Sedation Subscale	8.07; 6.70; 6.89	—
PRIMARY Biphasic Effects of Alcohol--Sedation Subscale	8.07; 6.70; 6.89	—
PRIMARY Biphasic Effects of Alcohol--Sedation Subscale	8.07; 6.70; 6.89	—
PRIMARY Biphasic Effects of Alcohol--Sedation Subscale	8.07; 6.70; 6.89	—
PRIMARY Biphasic Effects of Alcohol--Sedation Subscale	8.07; 6.70; 6.89	—
PRIMARY Alcohol Urge Questionnaire (AUQ	17.04; 17.41; 15.59	—
PRIMARY Alcohol Urge Questionnaire (AUQ	17.04; 17.41; 15.59	—
PRIMARY Alcohol Urge Questionnaire (AUQ	17.04; 17.41; 15.59	—
PRIMARY Alcohol Urge Questionnaire (AUQ	17.04; 17.41; 15.59	—
PRIMARY Alcohol Urge Questionnaire (AUQ	17.04; 17.41; 15.59	—
PRIMARY Alcohol Urge Questionnaire (AUQ	17.04; 17.41; 15.59	—
PRIMARY Alcohol Urge Questionnaire (AUQ	17.04; 17.41; 15.59	—
PRIMARY Alcohol Urge Questionnaire (AUQ	17.04; 17.41; 15.59	—
PRIMARY Alcohol Urge Questionnaire (AUQ	17.04; 17.41; 15.59	—

Summary

The main objectives of this study were to test if 2 different doses of Cannabidiol (compared to placebo) alter 1) breath alcohol concentration, 2) craving and subjective responses to alcohol or 3) cognitive performance following a standard dose of alcohol.

Eligibility Criteria

Inclusion Criteria

21-60 years old
able to provide consent
willing to consume CBD during the study
report heavy drinking (>5 drinks [>4 for women] per occasion on at least 5 days/month in the past 3 months)
not cannabis/CBD naive (i.e. THC or CBD use at least once in the past year), do not use cannabis regularly (i.e., less than monthly over past year), and no past-month cannabis use.

Exclusion Criteria

a regular or recent cannabis user (i.e. they used cannabis more often than monthly during the past year or used cannabis in the past month)
were seeking treatment a substance use disorder (SUD) including AUD, taking medications to treat bipolar or psychotic disorders
using nicotine every day
taking blood thinning medications
reported having a major medical condition contraindicating alcohol or CBD use (e.g., liver disease or heart disease)
reported current suicidality
met criteria for psychotic disorder, bipolar disorder or a current major depressive episode,
reported using illicit drugs in the 30 days prior to beginning the study or tested positive for any illicit drugs
were pregnant, breastfeeding or trying to become pregnant.

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT06105138). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.